



(12) Translation of
European patent specification

(11) NO/EP 3004155 B1

NORWAY

(19) NO
(51) Int Cl.
A61P 3/04 (2006.01)
A61K 38/00 (2006.01)
A61P 3/10 (2006.01)
A61P 43/00 (2006.01)
C07K 14/605 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2022.01.10

(80) Date of The European Patent Office Publication of the Granted Patent 2021.11.24

(86) European Application Nr. 14729976.2

(86) European Filing Date 2014.05.27

(87) The European Application's Publication Date 2016.04.13

(30) Priority 2013.05.28, JP, 2013111893

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

Designated Extension States: BA ; ME

(73) Proprietor Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka 541-0045, Japan

(72) Inventor ASAMI, Taiji, Fujisawa Kanagawa 251-0012, Japan
NIIDA, Ayumu, Fujisawa Kanagawa 251-0012, Japan

(74) Agent or Attorney Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54) Title **PEPTIDE COMPOUND**

(56) References Cited: WO-A2-2012/088379
WO-A2-2010/011439
AL-SABAH SULEIMAN ET AL: "A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS; GB, vol. 140, no. 2, 1 September 2003 (2003-09-01), pages 339-346, XP002437826, ISSN: 0007-1188, DOI: 10.1038/SJ.BJP.0705453
STEFFEN RUNGE ET AL: "Differential Structural Properties of GLP-1 and Exendin-4 Determine Their Relative Affinity for the GLP-1 Receptor N-Terminal Extracellular Domain +", BIOCHEMISTRY, vol. 46, no. 19, 1 May 2007 (2007-05-01), pages 5830-5840, XP055138608, ISSN: 0006-2960, DOI: 10.1021/bi062309m

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Peptid valgt fra

H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH₂ eller et salt derav,

H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Ile-Aib-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH₂ eller et salt derav,

H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH₂ eller et salt derav, og

H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ eller et salt derav.

2. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH₂ eller et salt derav.

3. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Ile-Aib-Leu-Asp-Lys-Gln-Ala-Gln-Ala-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH₂ eller et salt derav.

4. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH₂ eller et salt derav.

5. Peptidet eller saltet ifølge krav 1, som er H-Tyr-Aib-Glu-Gly-Thr- α MePhe-Thr-Ser-Asp-Tyr-Aib-Lys-Tyr-Leu-Asp-Lys-Gln-Ala-Gln-Gln-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ eller et salt derav.

6. Medikament omfattende peptidet ifølge krav 1 eller et salt derav.

7. Medikamentet ifølge krav 6, for anvendelse i profylaksen eller behandlingen av fedme eller diabetes.

8. Peptidet ifølge krav 1 eller et salt derav for anvendelse i profylaksen eller behandlingen av fedme eller diabetes.

9. Sammensetning omfattende peptidet ifølge krav 1 eller et salt derav og et ledsagende legemiddel.